Cancer-associated fibroblasts and extracellular matrix remodeling driving drug resistance and immune evasion in bladder cancer: research progress
Abstract
Drug resistance and immune evasion remain major obstacles to the effective treatment of bladder cancer. Cancer-associated fibroblasts (CAFs) are key stromal cells that reshape the tumor microenvironment through extracellular matrix (ECM) deposition and the secretion of cytokines, growth factors, and extracellular vesicles. These activities increase matrix stiffness, alter drug distribution, and restrict immune-cell infiltration and function. This review examines how CAF-driven ECM remodeling contributes to drug resistance and immune evasion in bladder cancer. We focus on collagen deposition and crosslinking, hyaluronic acid accumulation, dysregulated matrix degradation, and associated signaling pathways, including TGF-β, Hedgehog, Wnt, and Notch. We also discuss emerging therapeutic strategies targeting CAFs or ECM components, including matrix-modifying agents, advanced drug-delivery systems, and combination immunotherapies. By integrating mechanistic, translational, and clinical evidence, this review summarizes the current understanding of the CAF–ECM axis and identifies the principal uncertainties that must be addressed before stromal-directed approaches can be incorporated into bladder cancer treatment.
Related
- Extracellular matrix composition is associated with tissue-specific decellularization susceptibility and mechanical remodeling across human urogenital tissues
- Oral inulin prebiotic encapsulating Cortex Fraxini extracellular vesicles alleviates colitis and associated renal stress via reinforcing intestinal barriers and remodeling microbiota.
- Multidrug resistance and lipopolysaccharide remodeling associated with mcr-1 acquisition in Shiga toxin-producing Escherichia coli
- Transient 5-azacytidine exposure elicits persistent myogenic-like transcriptional remodeling in zebrafish fibroblasts: implications for cultivated seafood
- Epigenetic Remodeling Increases Plasticity of Bovine Fibroblasts Without Improving Embryo and Stem Cell Development
BibTeX
@article{lu2026cancerassociated,
title = {{Cancer-associated fibroblasts and extracellular matrix remodeling driving drug resistance and immune evasion in bladder cancer: research progress}},
author = {Pengcheng Lu and Liang Zhou},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.1941274},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1941274},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Cancer-associated fibroblasts and extracellular matrix remodeling driving drug resistance and immune evasion in bladder cancer: research progress
AU - Pengcheng Lu
AU - Liang Zhou
PY - 2026
DA - 2026/11/04
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1941274
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1941274
AB - Drug resistance and immune evasion remain major obstacles to the effective treatment of bladder cancer. Cancer-associated fibroblasts (CAFs) are key stromal cells that reshape the tumor microenvironment through extracellular matrix (ECM) deposition and the secretion of cytokines, growth factors, and extracellular vesicles. These activities increase matrix stiffness, alter drug distribution, and restrict immune-cell infiltration and function. This review examines how CAF-driven ECM remodeling contributes to drug resistance and immune evasion in bladder cancer. We focus on collagen deposition and crosslinking, hyaluronic acid accumulation, dysregulated matrix degradation, and associated signaling pathways, including TGF-β, Hedgehog, Wnt, and Notch. We also discuss emerging therapeutic strategies targeting CAFs or ECM components, including matrix-modifying agents, advanced drug-delivery systems, and combination immunotherapies. By integrating mechanistic, translational, and clinical evidence, this review summarizes the current understanding of the CAF–ECM axis and identifies the principal uncertainties that must be addressed before stromal-directed approaches can be incorporated into bladder cancer treatment.
SN - 1664-3224
ER -